In bladder cancer, METTL3 accelerates pri-miR221/222 maturation through m6A modification, which downregulates PTEN expression through miR221/222 binding to its 3’UTR and stimulates proliferation in vitro and in vivo [63]. The gene discussed is METTL3; the disease is urinary bladder cancer.